On Thursday, Level 3 Communications, Inc. (NYSE:LVLT)’s shares inclined 0.95% to $55.26.
Global telecommunications provider Level 3 Communications, Inc., (LVLT) declared the formation of the Level 3 Foundation Inc., a 501(c)(3) public charity. The Foundation was established to amplify the efforts of Level 3 Cares, the company’s corporate social responsibility program that launched in 2012, and give back to the communities where its employees live and work.
The mission of the Foundation is to provide employees and community members the opportunity to be kind to their neighbors and share in the company’s commitment to giving back. Both company employees and community members can contribute financially to the Foundation to support any of the identified cause areas: animal welfare, arts and culture, disaster relief, education, health and disease, natural environment and the underprivileged. Level 3 will match up to $250,000 of all employee contributions made to the Level 3 Foundation this year.
Level 3 believes a company culture based on core values not only assists its business, but also defines the role it can play in society. These core values – accountability, integrity, performance, respect, service and teamwork – assisted lay the groundwork for the Foundation and its mission.
Level 3 Communications, Inc., together with its auxiliaries, operates as a facilities-based provider of a range of integrated communications services primarily in North America, Latin America, Europe, the Middle East, and Africa. The company provides transport services comprising wavelengths, private lines, transoceanic, and dark fiber, in addition to related professional services; fiber services; and colocation and data center services, such as cloud, hosting, and application administration solutions.
Merrimack Pharmaceuticals Inc (NASDAQ:MACK)’s shares gained 10.22% to $12.19.
Merrimack Pharmaceuticals Inc (MACK) declared the election of John M. Dineen to its Board of Directors. Dineen, the former Chief Executive Officer of GE Healthcare, presently serves as an Operating Advisor to Clayton, Dublier & Rice, LLC.
Dineen led several of the top businesses during his career at GE. he served as the CEO of GE Healthcare, an $18 billion global healthcare business. Formerly, he was the CEO of GE Transportation, President of GE Plastics, General Manager of GE’s Power Equipment business and General Manager of GE’s Appliances, Microwave and Air-Conditioning businesses. He also served in various assignments in Corporate Finance, counting Manager of Finance for GE Asia in Hong Kong. Dineen is a graduate of the University of Vermont, where he earned bachelor’s degrees in biological sciences and computer science.
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. Its therapeutic oncology candidates in clinical development comprise MM-398, a nanotherapeutic encapsulation of the chemotherapy drug irinotecan, which is has accomplished Phase III clinical trials for the treatment of patients with metastatic pancreatic cancer whose cancer had progressed on treatment with the chemotherapy drug gemcitabine; in a Phase I clinical trial as a monotherapy in patients with glioma and in combination with cyclophosphamide in patients with pediatric solid tumors; and in a Phase 1 translational clinical trial designed to identify predictive biomarkers associated with MM-398.
At the end of Thursday’s trade, POZEN Inc. (NASDAQ:POZN)‘s shares surged 4.82% to $11.08.
POZEN Inc. (POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced the acquisition of Tribute Pharmaceuticals Canada Inc. a Canadian specialty pharmaceutical company, in a transaction valued at approximately US$146 million. Upon completion of the acquisition, which is expected to occur in the fourth quarter of 2015, the combined company will be named Aralez Pharmaceuticals plc (“Aralez” or the “Company”) and domiciled in Ireland. Upon closing, Aralez is expected to trade on NASDAQ and TSX.
The acquisition will create a premier specialty pharmaceutical company with a broad portfolio of commercial products and a growth plan focused on innovative products and acquisitions and the commercialization of portfolio products in the United States and Canada. The Company will also be well positioned to expand its foreign presence through potential international sales and licensing, manufacturing and product development.
Recently, POZEN’s lead proprietary product is YOSPRALA™, a coordinated-delivery tablet designed to provide the cardiovascular benefit of aspirin while reducing its gastrointestinal side effects. POZEN also has two commercial pain products, VIMOVO® and Treximet®, which are marketed by partners worldwide. Tribute’s highly complementary portfolio comprises Fibricor®, Bezalip® SR and Visken®/Viskazide® for various cardiovascular indications; Cambia® and Fiorinal® and Fiorinal® C for acute migraines and tension headaches, respectively; and a range of other specialty products. Tribute also is pursuing active and ongoing business development activities.
POZEN Inc., a pharmaceutical company, develops products for the treatment of acute and chronic pain, and pain related conditions in the United States and internationally. Its principal PA product candidates comprise PA32540 and PA8140 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, which have accomplished clinical development in the United States.
Mobile TeleSystems OJSC (ADR) (NYSE:MBT), ended its Thursday’s trading session with 3.56% gain, and closed at $10.19.
Mobile TeleSystems OJSC (ADR) (MBT) a global consulting, technology services and outsourcing company, declared that it was named to the “25 Most Promising Cloud Services Vendors 2015″ in the latest issue of Outsourcing Gazette, a print magazine which provides a platform to thinkers, practitioners, strategists and visionaries in the outsourcing community. Among the leading service providers dominating the landscape in the cloud space recently, Bell Integrator stood out as the “Company of the Month.”
By presenting the “25 Most Promising Cloud Services Vendors,” Outsourcing Gazette’s aim is to educate its audience about best of breed service providers for their needs and to assist CIOs select the right service provider from literally hundreds of vendors providing almost similar services.
A distinguished panel of CEOs, CIOs, Analysts and Industry Experts together with the Outsourcing Gazette editorial team selected Bell Integrator to the list noting the company’s service offering, core competencies, client testimonials and other industry recognitions.
Most recently Bell Integrator was honored with the IBM’s Best Partner Award in the IBM Cloud for Telecom category. These recognitions highlight Bell Integrator’s expertise and achievements in the cloud computing market.
Mobile TeleSystems OJSC provides telecommunication services in Russia and the Commonwealth of Independent States. The company offers a range of mobile and fixed line voice and data telecommunications services, counting data transfer, broadband, pay-TV, and various value-added services, in addition to sells equipment and accessories.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
